Corporate$SLN7:55 AM ETdeveloping · v3

Silence Therapeutics to be acquired for $20/ADS in all-cash deal valued at $1.3B

By BORSA NewsroomPublished Oct 19, 2026, 7:55 AM EDTUpdated Oct 19, 2026, 7:55 AM EDT

Silence Therapeutics PLC ADR (SLN) halted then announced an all-cash acquisition at $20 per ADS, a 130% premium to the Oct 16 close, valuing the company at about $1.3 billion.

Sentimentbullish 90

Strongly bullish · 90 of 100

Impact80

high · market-wide

Confidence90%

high confidence · 3 wires

Eventdeveloping

v3 · alerted to followers

WHAT WE KNOW

SLN halted pending news.
All-cash transaction at $20 per ADS.
130% premium to Oct 16 close.